---
title: "PSMA-Targeted Amanitin Fc–SMDC with Noncleavable Linker for Prostate Cancer Therapy"
id: "pubmed-41841414"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-41841414"
content_type: "clinical_feed_article"
specialty: "Pharmacology"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/41841414/"
doi: "10.1158/1535-7163.MCT-25-1274"
published_at: "2026-09-02T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# PSMA-Targeted Amanitin Fc–SMDC with Noncleavable Linker for Prostate Cancer Therapy
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-41841414
- **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/41841414/)
- **DOI:** [10.1158/1535-7163.MCT-25-1274](https://doi.org/10.1158%2F1535-7163.MCT-25-1274)
- **Published At:** 2026-09-02T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- Prostate cancer has limited options in advanced stages; targeted therapies aim to improve survival and quality of life. - Antibody-drug conjugates (ADC) have clinical success but limited efficacy in prostate cancer due to poor tumor penetration from large size. - Small molecule-drug conjugates (SMDC) offer better tumor penetration but suffer from short plasma half-life and limited clinical efficacy. - Fragment crystallizable–grafted SMDCs (Fc-SMDC) extend half-life by adding an antibody **Fc** fragment, but prior designs used enzyme-cleavable linkers, requiring payload release mechanisms. - The investigators report a first-in-class **Fc-SMDC** that targets **PSMA** and carries **α-amanitin** attached via a **noncleavable linker**. - Payload is conjugated directly to an engineered cysteine in the Fc region, physically separated from the targeting small molecule to permit a noncleavable linker strategy. - Use of a **noncleavable linker** aims to minimize premature drug release, increase plasma stability, and reduce systemic toxicity compared with cleavable-linker designs. - In preclinical studies the conjugate demonstrated high tolerability, extended plasma half-life, prolonged tumor exposure, and strong antitumor efficacy in xenograft models. - Favorable tolerability was also reported in non-human primates, supporting potential translation as a next-generation treatment for prostate cancer. - Article metadata: Mol Cancer Ther. 2026 Sep 2;25(9):1433-1446. DOI 10.1158/1535-7163.MCT-25-1274. PMID 41841414.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/41841414/#article-details) ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F41841414%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/41841414/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/41841414/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/41841414/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/af7de7da-df5d-41c6-8de4-8c266af8ccfb/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/41841414/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/41841414/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/41841414/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F41841414%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F41841414%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/41841414/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/41841414/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/41841414/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/41841414/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Full text links [![Silverchair Information Systems full text link](https://cdn.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--aacrjournals.org-images-pubmed-molcanther_full.gif) Silverchair Information Systems ](https://aacrjournals.org/mct/article-lookup/doi/10.1158/1535-7163.MCT-25-1274 "See full text options at Silverchair Information Systems") [ Full text links ](https://pubmed.ncbi.nlm.nih.gov/41841414/) ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/41841414/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/41841414/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/41841414/#abstract) * [Similar articles](https://pubmed.ncbi.nlm.nih.gov/41841414/#similar) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/41841414/#mesh-terms) * [ Substances ](https://pubmed.ncbi.nlm.nih.gov/41841414/#substances) * [Related information](https://pubmed.ncbi.nlm.nih.gov/41841414/#related-links) * [ Grants and funding ](https://pubmed.ncbi.nlm.nih.gov/41841414/#grants) * [ LinkOut - more resources ](https://pubmed.ncbi.nlm.nih.gov/41841414/#linkout) Title & authors Abstract Similar articles MeSH terms Substances Related information Grants and funding LinkOut - more resources Mol Cancer Ther Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Mol+Cancer+Ther%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Mol+Cancer+Ther%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/41841414/) . 2026 Sep 2;25(9):1433-1446. doi: 10.1158/1535-7163.MCT-25-1274. # Amanitin-Based Fc-Small Molecule-Drug Conjugates with Noncleavable Linker: A Novel Therapeutic Strategy for Prostate Cancer Targeted Therapy [Daniela Carraturo](https://pubmed.ncbi.nlm.nih.gov/?term=Carraturo+D&cauthor_id=41841414)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/41841414/#full-view-affiliation-1 "Department of Biochemistry and Cell Biology, Heidelberg Pharma Research GmbH, Ladenburg, Germany."), [Francesca Gallo](https://pubmed.ncbi.nlm.nih.gov/?term=Gallo+F&cauthor_id=41841414)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/41841414/#full-view-affiliation-2 "Department of Chemistry, Heidelberg Pharma Research GmbH, Ladenburg, Germany."), [Marisa Schmitt](https://pubmed.ncbi.nlm.nih.gov/?term=Schmitt+M&cauthor_id=41841414)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/41841414/#full-view-affiliation-3 "Department of Bioanalytics, Heidelberg Pharma Research GmbH, Ladenburg, Germany."), [Kristin Decker](https://pubmed.ncbi.nlm.nih.gov/?term=Decker+K&cauthor_id=41841414)[ 4 ](https://pubmed.ncbi.nlm.nih.gov/41841414/#full-view-affiliation-4 "Department of Non-Clinical Development, Heidelberg Pharma AG, Ladenburg, Germany."), [Christian Orlik](https://pubmed.ncbi.nlm.nih.gov/?term=Orlik+C&cauthor_id=41841414)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/41841414/#full-view-affiliation-1 "Department of Biochemistry and Cell Biology, Heidelberg Pharma Research GmbH, Ladenburg, Germany."), [Andreas M Pahl](https://pubmed.ncbi.nlm.nih.gov/?term=Pahl+AM&cauthor_id=41841414)[ 5 ](https://pubmed.ncbi.nlm.nih.gov/41841414/#full-view-affiliation-5 "Heidelberg Pharma AG, Ladenburg, Germany."), [Torsten Hechler](https://pubmed.ncbi.nlm.nih.gov/?term=Hechler+T&cauthor_id=41841414)[ 6 ](https://pubmed.ncbi.nlm.nih.gov/41841414/#full-view-affiliation-6 "ADC Research, Heidelberg Pharma Research GmbH, Ladenburg, Germany.") Affiliations Expand ### Affiliations * 1 Department of Biochemistry and Cell Biology, Heidelberg Pharma Research GmbH, Ladenburg, Germany. * 2 Department of Chemistry, Heidelberg Pharma Research GmbH, Ladenburg, Germany. * 3 Department of Bioanalytics, Heidelberg Pharma Research GmbH, Ladenburg, Germany. * 4 Department of Non-Clinical Development, Heidelberg Pharma AG, Ladenburg, Germany. * 5 Heidelberg Pharma AG, Ladenburg, Germany. * 6 ADC Research, Heidelberg Pharma Research GmbH, Ladenburg, Germany. * PMID: **41841414** * DOI: [ 10.1158/1535-7163.MCT-25-1274 ](https://doi.org/10.1158/1535-7163.mct-25-1274) Item in Clipboard # Amanitin-Based Fc-Small Molecule-Drug Conjugates with Noncleavable Linker: A Novel Therapeutic Strategy for Prostate Cancer Targeted Therapy Daniela Carraturo et al. Mol Cancer Ther. 2026. Show details Display options Display options Format Abstract PubMed PMID Mol Cancer Ther Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Mol+Cancer+Ther%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Mol+Cancer+Ther%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/41841414/) . 2026 Sep 2;25(9):1433-1446. doi: 10.1158/1535-7163.MCT-25-1274. ### Authors [Daniela Carraturo](https://pubmed.ncbi.nlm.nih.gov/?term=Carraturo+D&cauthor_id=41841414)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/41841414/#short-view-affiliation-1 "Department of Biochemistry and Cell Biology, Heidelberg Pharma Research GmbH, Ladenburg, Germany."), [Francesca Gallo](https://pubmed.ncbi.nlm.nih.gov/?term=Gallo+F&cauthor_id=41841414)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/41841414/#short-view-affiliation-2 "Department of Chemistry, Heidelberg Pharma Research GmbH, Ladenburg, Germany."), [Marisa Schmitt](https://pubmed.ncbi.nlm.nih.gov/?term=Schmitt+M&cauthor_id=41841414)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/41841414/#short-view-affiliation-3 "Department of Bioanalytics, Heidelberg Pharma Research GmbH, Ladenburg, Germany."), [Kristin Decker](https://pubmed.ncbi.nlm.nih.gov/?term=Decker+K&cauthor_id=41841414)[ 4 ](https://pubmed.ncbi.nlm.nih.gov/41841414/#short-view-affiliation-4 "Department of Non-Clinical Development, Heidelberg Pharma AG, Ladenburg, Germany."), [Christian Orlik](https://pubmed.ncbi.nlm.nih.gov/?term=Orlik+C&cauthor_id=41841414)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/41841414/#short-view-affiliation-1 "Department of Biochemistry and Cell Biology, Heidelberg Pharma Research GmbH, Ladenburg, Germany."), [Andreas M Pahl](https://pubmed.ncbi.nlm.nih.gov/?term=Pahl+AM&cauthor_id=41841414)[ 5 ](https://pubmed.ncbi.nlm.nih.gov/41841414/#short-view-affiliation-5 "Heidelberg Pharma AG, Ladenburg, Germany."), [Torsten Hechler](https://pubmed.ncbi.nlm.nih.gov/?term=Hechler+T&cauthor_id=41841414)[ 6 ](https://pubmed.ncbi.nlm.nih.gov/41841414/#short-view-affiliation-6 "ADC Research, Heidelberg Pharma Research GmbH, Ladenburg, Germany.") ### Affiliations * 1 Department of Biochemistry and Cell Biology, Heidelberg Pharma Research GmbH, Ladenburg, Germany. * 2 Department of Chemistry, Heidelberg Pharma Research GmbH, Ladenburg, Germany. * 3 Department of Bioanalytics, Heidelberg Pharma Research GmbH, Ladenburg, Germany. * 4 Department of Non-Clinical Development, Heidelberg Pharma AG, Ladenburg, Germany. * 5 Heidelberg Pharma AG, Ladenburg, Germany. * 6 ADC Research, Heidelberg Pharma Research GmbH, Ladenburg, Germany. * PMID: **41841414** * DOI: [ 10.1158/1535-7163.MCT-25-1274 ](https://doi.org/10.1158/1535-7163.mct-25-1274) Item in Clipboard Full text links Cite Display options Display options Format Abstract PubMed PMID ## Abstract Prostate cancer remains a major global health burden, with limited options and poor prognosis in advanced stages. To extend survival and improve the quality of life for patients, targeted therapies have become an emerging treatment modality. Antibody-drug conjugates (ADC) have shown huge clinical success but only limited therapeutic effects in prostate cancer as their large size limits tumor penetration. Small molecule-drug conjugates (SMDC), consisting of a small molecule as a binding moiety and a cytotoxic drug, offer advantages due to their smaller size, but their short plasma half-life and poor efficacy have hampered their clinical breakthrough so far. Fragment crystallizable (Fc)-grafted SMDCs (Fc-SMDC) combine a SMDC with the half-life-extending Fc fragment of an antibody. So far, the Fc fragments have been attached directly to the small molecule-drug complex, making an enzymatic cleavable linker for payload release an indispensable prerequisite. We report a first-in-class Fc-SMDC targeting PSMA and carrying α-amanitin with a noncleavable linker. The payload is conjugated directly to the Fc region via an engineered cysteine to separate it from the targeting moiety. This approach enables, in contrast to conventional Fc-SMDCs, the use of noncleavable linkers for minimal premature drug release, increased plasma stability, and low systemic toxicity. Due to the noncleavable linker, our conjugate showed high tolerability and an extended half-life, resulting in prolonged tumor exposure and excellent antitumor efficacy in xenograft models. Together with the favorable tolerability in non-human primates, these findings highlight the potential for a next-generation treatment for prostate cancer. ©2026 The Authors; Published by the American Association for Cancer Research. [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## Similar articles * [ PSMA-Targeted Small Molecule-Drug Conjugates Based on a Postprolyl Peptidase-Cleavable Linker for the Treatment of Prostate Cancer. ](https://pubmed.ncbi.nlm.nih.gov/40034039/) Georgiev T, Puglioli S, Principi L, Gilardoni E, Pellegrino C, Bassi G, Galbiati A, Neri D, Cazzamalli S.Georgiev T, et al.Mol Cancer Ther. 2025 Oct 1;24(10):1561-1569. doi: 10.1158/1535-7163.MCT-24-0750.Mol Cancer Ther. 2025.PMID: 40034039 * [ Small Molecule-Drug Conjugates: Opportunities for the Development of Targeted Anticancer Drugs. ](https://pubmed.ncbi.nlm.nih.gov/38396351/) Zhang J, Hu F, Aras O, Chai Y, An F.Zhang J, et al.ChemMedChem. 2024 Jun 3;19(11):e202300720. doi: 10.1002/cmdc.202300720. Epub 2024 Mar 11.ChemMedChem. 2024.PMID: 38396351Review. * [ Enhancing the Pharmacokinetics and Antitumor Activity of an α-Amanitin-Based Small-Molecule Drug Conjugate via Conjugation with an Fc Domain. ](https://pubmed.ncbi.nlm.nih.gov/33755471/) Gallo F, Korsak B, Müller C, Hechler T, Yanakieva D, Avrutina O, Kolmar H, Pahl A.Gallo F, et al.J Med Chem. 2021 Apr 8;64(7):4117-4129. doi: 10.1021/acs.jmedchem.1c00003. Epub 2021 Mar 23.J Med Chem. 2021.PMID: 33755471 * [ Neutrophil elastase as a versatile cleavage enzyme for activation of αvβ3 integrin-targeted small molecule drug conjugates with different payload classes in the tumor microenvironment. ](https://pubmed.ncbi.nlm.nih.gov/38495100/) Rebstock AS, Wiedmann M, Stelte-Ludwig B, Wong H, Johnson AJ, Izumi R, Hamdy A, Lerchen HG.Rebstock AS, et al.Front Pharmacol. 2024 Mar 1;15:1358393. doi: 10.3389/fphar.2024.1358393. eCollection 2024.Front Pharmacol. 2024.PMID: 38495100Free PMC article. * [ Advances in non-radioactive PSMA-targeted small molecule-drug conjugates in the treatment of prostate cancer. ](https://pubmed.ncbi.nlm.nih.gov/37813074/) Chen M, Cai L, Xiang Y, Zhong L, Shi J.Chen M, et al.Bioorg Chem. 2023 Dec;141:106889. doi: 10.1016/j.bioorg.2023.106889. Epub 2023 Sep 27.Bioorg Chem. 2023.PMID: 37813074Review. [ See all similar articles ](https://pubmed.ncbi.nlm.nih.gov/?linkname=pubmed_pubmed&from_uid=41841414) ## MeSH terms * Animals Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Animals%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Animals) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/41841414/) * Antineoplastic Agents* / chemistry Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antineoplastic+Agents%2Fchemistry%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Antineoplastic+Agents) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/41841414/) * Antineoplastic Agents* / pharmacology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antineoplastic+Agents%2Fpharmacology%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Antineoplastic+Agents) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/41841414/) * Cell Line, Tumor Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Cell+Line%2C+Tumor%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Cell+Line%2C+Tumor) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/41841414/) * Humans Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Humans%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Humans) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/41841414/) * Immunoconjugates* / chemistry Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Immunoconjugates%2Fchemistry%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Immunoconjugates) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/41841414/) * Immunoconjugates* / pharmacology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Immunoconjugates%2Fpharmacology%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Immunoconjugates) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/41841414/) * Immunoglobulin Fc Fragments* / chemistry Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Immunoglobulin+Fc+Fragments%2Fchemistry%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Immunoglobulin+Fc+Fragments) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/41841414/) * Male Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Male%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Male) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/41841414/) * Mice Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Mice%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Mice) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/41841414/) * Molecular Targeted Therapy Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Molecular+Targeted+Therapy%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Molecular+Targeted+Therapy) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/41841414/) * Prostatic Neoplasms* / drug therapy Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Prostatic+Neoplasms%2Fdrug+therapy%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Prostatic+Neoplasms) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/41841414/) * Pros
## Related Clinical Research

- [Diabetes Mellitus and Cancer Risk: Epidemiology and Molecular Mechanisms](https://medichelpline.com/clinical-feed/pubmed-42364319.md) (DOI: 10.1016/j.bbrc.2026.154205)
- [CAR T Cells Targeting O-Glycosylated Fibronectin (Tn-FN) Show Potent Cytotoxicity and Synergy with](https://medichelpline.com/clinical-feed/pubmed-42397032.md) (DOI: 10.1158/2326-6066.CIR-26-0009)
- [PBMs to display TrumpRx prices; Bristol’s Zenbexus gets FDA accelerated approval](https://medichelpline.com/clinical-feed/stat-news-2-stat-pbms-agree-to-display-trumprx-drug-prices.md)
- [Neurocrine Biosciences: weighing benefit and risk for a rare-disease drug](https://medichelpline.com/clinical-feed/stat-news-2-stat-neurocrine-biosciences-and-the-delicate-balance-of-benefit-and-risk.md)
- [Predictors and Trends of One-Day Discharge After Radical Prostatectomy in SEER-Medicare Patients](https://medichelpline.com/clinical-feed/medrxiv-23-geographic-and-clinical-predictors-of-one-day-discharge-after-radical.md)

## Navigation
- [← Back to Pharmacology Feed](https://medichelpline.com/clinical-feed/pharmacology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.